Cancer + The KRAS-Variant
The KRAS-variant may help determine the best treatment for the 20-25% of cancer patients who carry this biomarker.
The KRAS-variant is NOT a KRAS mutation in a cancerous tumor. KRAS mutations in a tumor are not inherited. You can learn more about the difference between the KRAS-variant and KRAS mutations here.
In fact, recent research has shown that the KRAS-variant plays an important role in the body's response to cancer therapies by affecting an individual's immune system.
Specifically, studies have found that certain cancer medications are far more effective for KRAS-variant cancer patients, while others work poorly. The difference in taking the wrong versus the right cancer medicine if you are a KRAS-variant patient can lead to up to a 3-fold (300%) difference in your chance of survival.22,23
Research to determine which treatments work best for KRAS-variant patients have been conducted in breast,3 ovarian,22,25 colon,26-37 lung, and head and neck cancer.23,40,41 To read publications with findings about specific types of cancers, please go here.
Should you get tested for the KRAS-variant?
If you have history of breast, ovarian or lung cancer, learning whether you have the KRAS-variant can help you make the important decision about whether or not HRT is right for you.
Why join a MiraKind research study?
By joining a MiraKind study, you can play a role in helping MiraKind answer some of the most pressing questions associated with cancer risk for individuals with inherited variants like the KRAS-variant.